ATA91797A - Eine das vwf-propeptid enthaltende pharmazeutische präparation - Google Patents

Eine das vwf-propeptid enthaltende pharmazeutische präparation

Info

Publication number
ATA91797A
ATA91797A AT0091797A AT91797A ATA91797A AT A91797 A ATA91797 A AT A91797A AT 0091797 A AT0091797 A AT 0091797A AT 91797 A AT91797 A AT 91797A AT A91797 A ATA91797 A AT A91797A
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
vwf propeptide
vwf
propeptide
Prior art date
Application number
AT0091797A
Other languages
English (en)
Other versions
AT405485B (de
Inventor
Hans-Peter Schwarz
Katalin Dr Varadi
Peter Dr Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0091797A priority Critical patent/AT405485B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to PCT/EP1998/003090 priority patent/WO1998053848A1/en
Priority to CA002288737A priority patent/CA2288737A1/en
Priority to DE69802918T priority patent/DE69802918T2/de
Priority to AU79156/98A priority patent/AU744643B2/en
Priority to JP50022099A priority patent/JP4335978B2/ja
Priority to AT98929378T priority patent/ATE210455T1/de
Priority to EP98929378A priority patent/EP0977584B1/de
Priority to ES98929378T priority patent/ES2168766T3/es
Priority to US09/424,498 priority patent/US7005502B1/en
Publication of ATA91797A publication Critical patent/ATA91797A/de
Application granted granted Critical
Publication of AT405485B publication Critical patent/AT405485B/de
Priority to NO19995843A priority patent/NO324064B1/no
Priority to US11/218,406 priority patent/US7557188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0091797A 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation AT405485B (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
ES98929378T ES2168766T3 (es) 1997-05-28 1998-05-26 Preparacion farmaceutica que incluye el propeptido vwf.
DE69802918T DE69802918T2 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
AU79156/98A AU744643B2 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vWF propeptide
JP50022099A JP4335978B2 (ja) 1997-05-28 1998-05-26 ｖＷＦプロペプチドを含む医薬調製物
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE
CA002288737A CA2288737A1 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vwf propeptide
US09/424,498 US7005502B1 (en) 1997-05-28 1998-05-26 Pharmaceutical preparation comprising vWF propeptide
EP98929378A EP0977584B1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat
NO19995843A NO324064B1 (no) 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav
US11/218,406 US7557188B2 (en) 1997-05-28 2005-09-01 Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation

Publications (2)

Publication Number Publication Date
ATA91797A true ATA91797A (de) 1999-01-15
AT405485B AT405485B (de) 1999-08-25

Family

ID=3502803

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98929378T ATE210455T1 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Country Status (10)

Country Link
US (2) US7005502B1 (de)
EP (1) EP0977584B1 (de)
JP (1) JP4335978B2 (de)
AT (2) AT405485B (de)
AU (1) AU744643B2 (de)
CA (1) CA2288737A1 (de)
DE (1) DE69802918T2 (de)
ES (1) ES2168766T3 (de)
NO (1) NO324064B1 (de)
WO (1) WO1998053848A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1240900B1 (de) * 1999-12-24 2009-05-06 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
CN101163506B (zh) 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2349314B1 (de) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
CA2741634A1 (en) * 2008-10-27 2010-06-03 Baxter International Inc. Models of thrombotic thrombocytopenic purpura and methods of use thereof
DK2467399T3 (en) 2009-08-20 2017-01-23 Baxalta Inc Purification of vWF for increased removal of non-lipid-enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017055072A1 (en) 2015-10-02 2017-04-06 Asml Netherlands B.V. Metrology method and apparatus, computer program and lithographic system
KR102788331B1 (ko) 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
EP4424366A3 (de) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Behandlung von gastrointestinalen blutungen bei patienten mit schwerer von-willebrand-krankheit durch verabreichung von rekombinantem vwf
IL277464B1 (en) 2018-03-21 2026-04-01 Baxalta Inc Separation of VWF and VWF propeptide using chromatographic methods
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
CN114929260A (zh) 2019-09-11 2022-08-19 武田药品工业株式会社 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) * 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase

Also Published As

Publication number Publication date
EP0977584A1 (de) 2000-02-09
ATE210455T1 (de) 2001-12-15
WO1998053848A1 (en) 1998-12-03
AU744643B2 (en) 2002-02-28
NO324064B1 (no) 2007-08-06
EP0977584B1 (de) 2001-12-12
NO995843L (no) 2000-01-27
ES2168766T3 (es) 2002-06-16
CA2288737A1 (en) 1998-12-03
AU7915698A (en) 1998-12-30
DE69802918T2 (de) 2003-04-10
DE69802918D1 (de) 2002-01-24
JP2001527579A (ja) 2001-12-25
JP4335978B2 (ja) 2009-09-30
NO995843D0 (no) 1999-11-29
AT405485B (de) 1999-08-25
US7005502B1 (en) 2006-02-28
US7557188B2 (en) 2009-07-07
US20060003921A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE69814394D1 (de) Verwendung von levobupivacain
FI952169L (fi) Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi
IT8123070A0 (it) Preparato che favorisce la coagulazione del sangue a base di proteine umani, nonche'procedimento per la preparazione
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
IT1198233B (it) Metodo per la determinazione di anticorpi antisporozoita di p. falciparum nel sangue umano
NO881768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
NO871477D0 (no) Fremgangsmaate for fremstilling av human plasminogenaktivator.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3771266D1 (de) Medizinisches instrument zum ausschneiden von knochengewebe.
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
DE3668338D1 (de) Kontinuierliche behandlung von spannungslosem gewebe.
NO880639D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive oksimetere av 2,6-dioksabicyklo (3, 3, 0)oktanoner.
FI851969A7 (fi) Korkean verenpaineen hoitoon soveltuvia tetrahydronaftalenoleja.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
EIH Change in the person of patent owner
PC Change of the owner

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160623

Owner name: BAXALTA GMBH, CH

Effective date: 20160623

MK07 Expiry

Effective date: 20170528